Chemokines in pathogenesis of Experimental Arthritis

实验性关节炎发病机制中的趋化因子

• 批准号: 7906054
• 负责人: SEEMA Singh AHUJA
• 金额: $ 38.02万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-19 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7906054
• 关键词: Address; Affect; Affinity; Animal Model; Animals; Antibodies; Antigen-Antibody Complex; Antigen-Presenting Cells; Antigens; Apoptosis; Area; Arthritis; Arts; Autoimmune Process; Autoimmune Responses; Backcrossings; Biological Models; Biology; C-reactive protein; CC chemokine receptor 2; CCL2 gene; Cartilage; Cell physiology; Cells; Characteristics; Chemicals; Chronic; Clinical; Clinical Trials; Collagen; Collagen Arthritis; Communicable Diseases; Complement; Defect; Dendritic Cells; Deposition; Development; Disease; Doctor of Medicine; Employee Strikes; Ensure; Environmental Risk Factor; Event; Experimental Arthritis; Generations; Genetic; Goals; HIV; Human; Hyperplasia; Image; Immune response; Immunity; Immunology; Infection; Inflammation; Inflammatory; Inflammatory Response; Joints; Kinetics; Knock-out; Knockout Mice; Knowledge; Lead; Leukocytes; Ligands; Light; Link; Literature; Maintenance; Mediating; Modeling; Molecular; Molecular Mimicry; Morbidity - disease rate; Mus; Pathogenesis; Patients; Phase; Phase I/II Trial; Phase II Clinical Trials; Phenotype; Play; Population; Positron-Emission Tomography; Process; Publishing; Research; Research Design; Resolution; Rheumatoid Arthritis; Rheumatoid Factor; Role; Staging; Stress; Study Section; System; T-Lymphocyte; Techniques; Testing; Therapeutic; Time; Wild Type Mouse; activity marker; base; beta-Chemokines; bone; cell type; chemokine; chemokine receptor; clinical efficacy; clinically relevant; direct application; expectation; in vivo; innovation; interest; macrophage; member; migration; monocyte; monocyte chemoattractant protein 1 receptor; mortality; neovascularization; novel; programs; receptor; response; stem; therapeutic target; therapy design

DESCRIPTION (provided by applicant): Monocyte chemotactic protien-1 (MCP-1/CCL2) and its high affinity receptor CCR2 play a critical role in leukocyte migration and the generation of inflammatory response. The role of MCP-1/CCR2 axis in resolution of inflammation has not been explored. In three different murine models of arthritis I have shown that genetic inactivation of the CC chemokine receptor (CCR)2 leads to a more severe chronic persistent arthritis. Genetic inactivation of CCR2 results not only in substantial disruptions in Dendritic Cells (DC) and monocyte migration, but also, the CCR2 null state is characterized by the loss of a subtype of DCs implicated in the generation of tolerance. We surmised that because DC and monocytes play critical roles in the different phases of RA and CIA, defects in these cell types occurring as part of the CCR2 null state may greatly contribute to the more severe arthritic phenotype seen in CCR2 KO mice. Thus, in this application we will focus on teasing apart the potential mechanisms by which CCR2 modulates arthritis. To do so we will address the following two Specific Aims : Aim #1 will test the hypothesis that the regulatory role of CCR2 in experimental arthritis is mediated in part via its effects on DCs and/or monocyte macrophage biology. Aim #2 will test the hypothesis that CCR2-dependent cellular processes modulate the kinetics of arthritogenic antibodies deposition and /or clearance. The studies proposed are significant because they will capitalize on our expertise in immunology, chemokine biology and small animal imaging to fill important knowledge gaps in RA pathogenesis, and they are relevant because they address a critical area in chemokine biology with potential therapeutic implications, namely the pathogenic link between CCR2 and RA pathogenesis. The proposed research is innovative because it utilizes state-of-the-art techniques using MicroSPECT, PET and CT imaging for small animals. Rheumatoid Arthritis affects 1% of US population, and therapies designed to block CCR2 are in phase II clinical trials. Thus information obtained from proposed studies which explore how CCR2 modulates arthritis will have significant impact on potential therapeutic strategies to treat this chronic deblitating disease.

描述（申请人提供）：单核细胞趋化蛋白-1（MCP-1/CCL2）及其高亲和力受体CCR2在白细胞迁移和炎症反应的产生中发挥关键作用。 MCP-1/CCR2 轴在炎症消退中的作用尚未被探索。在三种不同的小鼠关节炎模型中，我发现 CC 趋化因子受体 (CCR)2 的基因失活会导致更严重的慢性持续性关节炎。 CCR2 的基因失活不仅会导致树突状细胞 (DC) 和单核细胞迁移的严重破坏，而且 CCR2 无效状态的特点是丢失与耐受性产生有关的 DC 亚型。我们推测，由于 DC 和单核细胞在 RA 和 CIA 的不同阶段发挥着关键作用，作为 CCR2 无效状态一部分而发生的这些细胞类型的缺陷可能会极大地导致 CCR2 KO 小鼠中出现的更严重的关节炎表型。因此，在本申请中，我们将重点梳理 CCR2 调节关节炎的潜在机制。为此，我们将解决以下两个具体目标：目标 #1 将测试以下假设：CCR2 在实验性关节炎中的调节作用部分是通过其对 DC 和/或单核巨噬细胞生物学的影响来介导的。目标 #2 将检验以下假设：CCR2 依赖性细胞过程调节致关节炎抗体沉积和/或清除的动力学。所提出的研究意义重大，因为它们将利用我们在免疫学、趋化因子生物学和小动物成像方面的专业知识来填补 RA 发病机制的重要知识空白，并且它们具有相关性，因为它们解决了趋化因子生物学中具有潜在治疗意义的关键领域，即CCR2 和 RA 发病机制之间的致病联系。拟议的研究具有创新性，因为它利用了最先进的 MicroSPECT、PET 和 CT 成像技术对小动物进行成像。类风湿性关节炎影响着 1% 的美国人口，旨在阻断 CCR2 的疗法正处于 II 期临床试验中。因此，从探索 CCR2 如何调节关节炎的拟议研究中获得的信息将对治疗这种慢性衰弱性疾病的潜在治疗策略产生重大影响。

项目成果

Critical role of chemokine (C-C motif) receptor 2 (CCR2) in the KKAy + Apoe -/- mouse model of the metabolic syndrome.

• DOI: 10.1007/s00125-011-2248-8
• 发表时间: 2011-10
• 期刊: DIABETOLOGIA
• 影响因子: 8.2
• 作者: Martinez, H. G.;Quinones, M. P.;Jimenez, F.;Estrada, C. A.;Clark, K.;Muscogiuri, G.;Sorice, G.;Musi, N.;Reddick, R. L.;Ahuja, S. S.
• 通讯作者: Ahuja, S. S.

Important role of CCR2 in a murine model of coronary vasculitis.

• DOI: 10.1186/1471-2172-13-56
• 发表时间: 2012-10-17
• 期刊: BMC immunology
• 影响因子: 3
• 作者: Martinez HG;Quinones MP;Jimenez F;Estrada C;Clark KM;Suzuki K;Miura N;Ohno N;Ahuja SK;Ahuja SS
• 通讯作者: Ahuja SS